FY2025 Earnings Forecast for STOK Issued By Chardan Capital

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Equities researchers at Chardan Capital issued their FY2025 earnings per share estimates for shares of Stoke Therapeutics in a research report issued to clients and investors on Monday, March 24th. Chardan Capital analyst R. Li anticipates that the company will post earnings per share of ($1.75) for the year. Chardan Capital currently has a “Buy” rating and a $24.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.38. The firm had revenue of $22.61 million during the quarter, compared to analysts’ expectations of $4.20 million. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.

Several other analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $47.00 target price on shares of Stoke Therapeutics in a research report on Wednesday, March 19th. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday, March 18th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $24.67.

Stoke Therapeutics Price Performance

STOK opened at $7.45 on Thursday. The firm has a 50 day simple moving average of $9.36 and a 200 day simple moving average of $11.24. Stoke Therapeutics has a fifty-two week low of $7.18 and a fifty-two week high of $17.58. The company has a market cap of $402.88 million, a price-to-earnings ratio of -3.55 and a beta of 0.99.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. California State Teachers Retirement System grew its stake in Stoke Therapeutics by 16.2% during the fourth quarter. California State Teachers Retirement System now owns 32,068 shares of the company’s stock worth $354,000 after buying an additional 4,468 shares in the last quarter. Toronto Dominion Bank acquired a new stake in Stoke Therapeutics in the fourth quarter valued at about $35,001,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Stoke Therapeutics by 123.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company’s stock valued at $1,053,000 after purchasing an additional 52,813 shares during the last quarter. Squarepoint Ops LLC grew its position in Stoke Therapeutics by 6.7% during the 4th quarter. Squarepoint Ops LLC now owns 120,242 shares of the company’s stock worth $1,326,000 after acquiring an additional 7,575 shares during the last quarter. Finally, Tang Capital Management LLC acquired a new stake in shares of Stoke Therapeutics during the fourth quarter valued at about $3,309,000.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of the business’s stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the sale, the insider now owns 63,962 shares of the company’s stock, valued at $554,550.54. The trade was a 5.72 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction that occurred on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the transaction, the director now directly owns 148,253 shares in the company, valued at $1,285,353.51. This represents a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.